Compare WETH & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | CDT |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | China | United States |
| Employees | N/A | 6 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1M | 22.1M |
| IPO Year | 2020 | N/A |
| Metric | WETH | CDT |
|---|---|---|
| Price | $1.83 | $3.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.2K | ★ 98.0K |
| Earning Date | 04-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $45,136,818.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.65 | ★ N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $0.76 | $0.37 |
| 52 Week High | $3.68 | $11.00 |
| Indicator | WETH | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 70.68 | 50.08 |
| Support Level | $1.82 | $3.18 |
| Resistance Level | $1.85 | $4.50 |
| Average True Range (ATR) | 0.14 | 1.10 |
| MACD | 0.06 | -0.21 |
| Stochastic Oscillator | 90.67 | 11.98 |
Wetouch Technology Inc is a touch panel supplier focused on R&D, production, and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for the automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots, and charging stations. The company sells touchscreen products both domestically in China and internationally. The company generates the majority of its revenue from the PRC, followed by the Republic of China and Korea.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The group is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.